ReviewEnvironmental science & technology letters2022
GREENER Pharmaceuticals for More Sustainable Healthcare.
Review in Environmental science & technology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Greener active pharmaceutical ingredients: perspectives of European healthcare professionals.BMC health services research · 2026Article
- Advantages and drawbacks of life cycle assessment application to the pharmaceuticals: a short critical literature review.Environmental science and pollution research international · 2026Review
- Introducing an Expanded Value Framework in Health Technology Assessment of Vaccines.Journal of market access & health policy · 2026Article
- Braiding Knowledge Systems: Integrating Indigenous Wisdom and Sustainable Research for a Regenerative Future.ACS sustainable chemistry & engineering · 2026Review
- Age-Specific Association Between Urinary Phthalate Metabolites and Diabetes Mellitus: Findings from the Korean National Environmental Health Survey Cycle 4 (2018-2020).Healthcare (Basel, Switzerland) · 2026Article
- Breaking Lock-ins to Enable a Green Pharmacy.Environmental science & technology · 2026Review
- AI-enabled, QbD-aligned Predictive, and Sustainable Design of Natural Polymer-based Drug Delivery Systems.AAPS PharmSciTech · 2026Review
- Educational exposure and sustainability-related outcomes among pharmacy students in Bulgaria: a cross-sectional study.Frontiers in public health · 2026Article
- Reimagining Social Value to Consider the Environment: How Should We Judge the Magnitude of Benefits in Health Research?Bioethics · 2025Article
- Generation and Use of Bicyclo[1.1.0]butyllithium under Continuous Flow Conditions.Organic letters · 2025Article
- Pharmaceutical waste management through microbial bioremediation.Environmental monitoring and assessment · 2025Review
- Read-Across of Biotransformation Potential between Activated Sludge and the Terrestrial Environment: Toward Making It Practical and Plausible.Environmental science & technology · 2025Article
- Tackling Pharmaceutical Pollution Along the Product Lifecycle: Roles and Responsibilities for Producers, Regulators and Prescribers.Pharmacy (Basel, Switzerland) · 2024Article
- Harnessing the 12 Green Chemistry Principles for Sustainable Antiparasitic Drugs: Toward the One Health Approach.ACS infectious diseases · 2024Review
- Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives.International journal of molecular sciences · 2024Review
- A review on emerging pharmaceutical residues in Ethiopia: occurrence, ecotoxicological aspects, and regulatory concerns.Frontiers in microbiology · 2024Review
- Environmental impacts of drugs against parasitic vector-borne diseases and the need to integrate sustainability into their development and use.Open research Europe · 2024Article
- Photodegradable antimicrobial agents: towards structure optimization.RSC advances · 2023Article
- enviRule: an end-to-end system for automatic extraction of reaction patterns from environmental contaminant biotransformation pathways.Bioinformatics (Oxford, England) · 2023Article
- The Dutch chain approach on pharmaceuticals in water: Stakeholders acting together to reduce the environmental impact of pharmaceuticals.British journal of clinical pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.